OGN
Organon & CoNYSE
Healthcare • Drug Manufacturers - General
Factor tilt: Mid-Cap Blend
$13.87+0.58%
Close Nov 6, 2026
- Market cap
- $3.64B
- 1 month
- +0.9%
- 3 months
- +1.8%
- 1 year
- +117.4%
- 52-week range
- $5.70$13.87
- Dividend, last 12 mo
- $0.08 · 0.58% yield
- Last ex-date
- Aug 14, 2026 · $0.02
- Short interest
- 7.7% of float18.8M shares · settled Oct 15, 2026 · -0.8% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $6.1B
- Net income
- $213M
- Free cash flow
- $675M
- Book value
- $1.19B
- Total debt
- $8.55B
- P/E
- 17.1×
- Price / sales
- 0.6×
- Price / book
- 3.1×
- FCF yield
- +18.5%
- Net margin
- +3.5%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Read more
The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Website
- organon.com
- Headquarters
- Jersey City, NJ, United States
- Employees
- 10,000
- Listed
- Jun 2, 2021
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 1, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 30, 2026 | $1.6B | -1.7% | 55.2% | $365.0M | $164.0M |
| Jun 2026filed Jul 31, 2026 | $1.6B | -2.3% | 54.4% | $323.0M | $108.0M |
| Mar 2026filed May 4, 2026 | $1.5B | -3.5% | 53.6% | $266.0M | $146.0M |
| Dec 2025filed Feb 24, 2026 | $1.5B | -5.3% | 50.4% | $235.0M | -$205.0M |
| Sep 2025filed Nov 10, 2025 | $1.6B | +1.3% | 53.5% | $358.0M | $160.0M |
| Jun 2025filed Aug 6, 2025 | $1.6B | -0.8% | 54.8% | $326.0M | $145.0M |
| Mar 2025filed May 2, 2025 | $1.5B | -6.7% | 55.6% | $325.0M | $87.0M |
| Dec 2024filed Feb 28, 2025 | $1.6B | -0.4% | 56.3% | $296.0M | $109.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 24, 2026 | $6.2B | -2.9% | 54.1% | $1.3B | $187.0M |
| Dec 2024filed Feb 28, 2025 | $6.4B | +2.2% | 58.0% | $1.5B | $864.0M |
| Dec 2023filed Feb 26, 2024 | $6.3B | +1.4% | 59.8% | $1.3B | $1.0B |
| Dec 2022filed Feb 27, 2023 | $6.2B | -2.1% | 62.8% | $1.7B | $917.0M |
| Dec 2021filed Mar 21, 2022 | $6.3B | -3.5% | 62.2% | $1.9B | $1.4B |
| Dec 2020filed Dec 31, 2020 | $6.5B | -16.0% | 67.6% | $2.8B | $2.2B |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched OGN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
18,817,326 shares short
-143,770 shares (-0.8%) vs Sep 30, 2026
7.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
18,961,096 shares short
+1,431,357 shares (+8.2%) vs Sep 15, 2026
7.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
17,529,739 shares short
+834,561 shares (+5%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
16,695,178 shares short
+1,556,558 shares (+10.3%) vs Aug 14, 2026
6.4% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
15,138,620 shares short
-1,668,054 shares (-9.9%) vs Jul 31, 2026
5.8% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
16,806,674 shares short
+563,133 shares (+3.5%) vs Jul 15, 2026
6.4% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind OGN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
USD 0.02 per share
Ex-dividend date: Nov 9, 2026 (future recorded date)
Recorded pay date: Dec 10, 2026 (pending)
Cash dividend · Polygon event record
USD 0.02 per share
Ex-dividend date: Aug 14, 2026
Recorded pay date: Sep 10, 2026 (past date)
Cash dividend · Polygon event record
USD 0.02 per share
Ex-dividend date: May 11, 2026
Recorded pay date: Jun 11, 2026 (past date)
Cash dividend · Polygon event record
USD 0.02 per share
Ex-dividend date: Feb 23, 2026
Recorded pay date: Mar 12, 2026 (past date)
Cash dividend · Polygon event record
USD 0.02 per share
Ex-dividend date: Nov 20, 2025
Recorded pay date: Dec 11, 2025 (past date)
Cash dividend · Polygon event record
USD 0.02 per share
Ex-dividend date: Aug 15, 2025
Recorded pay date: Sep 11, 2025 (past date)
Cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if OGN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
69 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 2
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
631 filers reported a long position in OGN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
50.2%
of the 218.6M shares 13-F filers reported
Moves vs Q1 2026
5 added2 trimmed
3 new
Net shares held
-1.7%
across the 7 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $434M · 32.1M shares | 32.1M | +1.1% |
| 2 | Pentwater Capital Management LP | $245.1M · 18.1M shares | 18.1M | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $204.9M · 15.1M shares | 15.1M | -30.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $161.3M · 11.9M shares | 11.9M | +1.5% |
| 5 | STATE STREET CORP | $130.8M · 9.7M shares | 9.7M | -3% |
| 6 | GOLDMAN SACHS GROUP INC | $70.4M · 5.2M shares | 5.2M | +223.9% |
| 7 | UBS Group AG | $65.8M · 4.9M shares | 4.9M | +39.9% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $65.2M · 4.8M shares | 4.8M | +1.2% |
| 9 | Man Group plc | $56.6M · 4.2M shares | 4.2M | New |
| 10 | AQR Arbitrage LLC | $52.4M · 3.9M shares | 3.9M | New |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of OGN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 14, 2026 | Pentwater Capital Management LP13G · passive | 6.9% |
| Jul 31, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive · amended | 5.77% |
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.26% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for OGN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.